Sort
48,018 grants matching “immunotherapy”
Targeting heat shock factor 1 (HSF1) to increase tumor infiltrating lymphocytes in metastatic breast cancer.
$378,444Richard L Carpenter · Indiana University Indianapolis · R01 · FY2025 · CA
Retinal Remodeling
$378,438Bryan William Jones · University Of Utah · R01 · FY2017 · EY
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
$378,438Jonathan F Lovell · State University Of New York At Buffalo · R01 · FY2021 · CA
Core B: Computational
$378,433Alan S Perelson · Beth Israel Deaconess Medical Center · P01 · FY2017 · AI
Plasma Membrane Proteins in Myeloid-Derived Suppressor Cells
$378,429Catherine C. Fenselau · Univ Of Maryland, College Park · R01 · FY2010 · GM
Personalized targeting of anti-apoptosis pathways to overcome therapeutic resistance in melanoma
$378,415Michael Davies · Wistar Institute · U54 · FY2024 · CA
Rare Central Nervous System Cancers Initiative
$378,413Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Brain Tumor Immunotherapy
$378,413Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
$378,389Mark S Berger · Actinium Pharmaceuticals, Inc. · R42 · FY2020 · CA
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition
$378,369Robert M Prins · University Of California Los Angeles · P50 · FY2023 · CA
Telomerase RNA Transfected Dendritic Cell Vaccines
$378,363Duke University · R01 · FY2002 · CA
Combinatorial Beta Cell-Specific Cytokine Therapy to Reverse Type I Diabetes
$378,354Roland Michael Tisch · Univ Of North Carolina Chapel Hill · R01 · FY2018 · DK
Combinatorial Beta Cell-Specific Cytokine Therapy to Reverse Type I Diabetes
$378,354Roland Michael Tisch · Univ Of North Carolina Chapel Hill · R01 · FY2016 · DK
Combinatorial Beta Cell-Specific Cytokine Therapy to Reverse Type I Diabetes
$378,354Roland Michael Tisch · Univ Of North Carolina Chapel Hill · R01 · FY2017 · DK
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer
$378,315Weidong Xu · Endeavor Health Clinical Operations · R01 · FY2023 · CA
Controlled Release of Macromolecules
$378,300Robert S Langer · Massachusetts Institute Of Technology · R37 · FY2014 · EB
Immunomodulatory effects of arginine supplementation in colitis and colon cancer
$378,300Keith T Wilson · Vanderbilt University · R01 · FY2014 · AT
Electron microscopy of therapeutic and diagnostic nanoparticles
$378,299Richard Leapman · National Institute Of Biomedical Imaging And Bioengineering · ZIA · FY2018 · EB
Resource for Nonhuman Primate Immune Reagents
$378,290Francois J Villinger · University Of Louisiana At Lafayette · R24 · FY2017 · OD
Off-the-shelf iPSC-Derived Natural Killer Cell Immunotherapies for AML
$378,249Jeffrey S Miller · University Of Minnesota · P01 · FY2024 · CA
Targeting the immunosuppressive adenosine-axis to overcome T-cell γc cytokine signaling blockade and enhance antitumor immunity in hepatocellular carcinoma
$378,246Yong Qin · University Of Texas El Paso · U54 · FY2025 · MD
Monitoring neurochemical signaling dynamics in the lymph node
$378,222Ashley E Ross · University Of Cincinnati · R01 · FY2020 · AI
Targeting the liver for immunotherapy in pancreatic cancer
$378,219Gregory L Beatty · University Of Pennsylvania · R01 · FY2023 · CA
Biofilm Formation by Pneumocystis
$378,201Melanie T Cushion · University Of Cincinnati · R01 · FY2010 · AI
MECHANISMS OF NONSTERILIZING IMMUNITY IN MALARIA
$378,132University Of Wisconsin Madison · R01 · FY2001 · AI